Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients

Next Previous
Trial Profile

An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary) ; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AARON

Most Recent Events

  • 30 Apr 2025 Interim Results(n=12) assessing the safety and efficacy of AZA, nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) in R/R AML, and of AZA plus VEN in combination with nivolumab and relatlimab in non-fit patients with newly diagnosed wild-type IDH/NPM1 AML were presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 03 Nov 2022 Planned End Date changed from 31 Mar 2026 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top